Back to search resultsSummaryRMgm-4393
|
||||||||
*RMgm-4393| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 29233900 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. yoelii |
| Parent strain/line | P. y. yoelii 17XNL |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Zhang C; Yuan J |
| Name Group/Department | State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, Schoo |
| Name Institute | Xiamen University |
| City | Xiamen, Fujian |
| Country | China |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-4393 |
| Principal name | ΔPyap2-sp2 |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Normal numbers of oocysts. However, no sporozoite formation inside oocysts (oocyst became vacuolated). No salivary gland sporozoites. |
| Sporozoite | Normal numbers of oocysts. However, no sporozoite formation inside oocysts (oocyst became vacuolated). No salivary gland sporozoites. |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Other mutants |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PF3D7_0404100 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1350900 | ||||||||||||||||||||||||
| Gene product | AP2 domain transcription factor AP2-SP2, putative | ||||||||||||||||||||||||
| Gene product: Alternative name | ApiAP2; AP2-SP2 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | The gene has been disrupted using CRISPR/cas9 genome editing (using constructs as described for mutant RMgm-1095). To construct the vectors to disrupt the PyApiAP2 genes, we first amplified the 5'- and 3'-flanking genomic regions (400 to 700 bp) as left and right homologous arms. The left and right arms were inserted into the restriction sites (HindIII/KpnI and NcoI for the left arm and XhoI and AflII/EcoRI for the right arm) in the pYC plasmid (RMgm-1095). Sequences for single guide RNAs (sgRNAs) were similarly annealed and ligated into the pYC plasmid. | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||